![discount label](https://static.cymitquimica.com/public/img/discount.png)
Product Information
MYCi361 is an antibody-drug conjugate that targets the histone deacetylase. MYCi361 has been shown to be effective in treating leukocyte antigen (HLA)-expressing tumours, such as melanoma, colorectal cancer, and breast cancer that overexpress the HER2 receptor. MYCi361 blocks the biological activity of histone deacetylase by binding to it, which results in reduced expression of HLA proteins. This leads to tumor regression and prolonged survival in animal models.
Chemical properties
Technical inquiry about: 3D-PRD69031 MYCi361
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.